Core Points - Cellectis held a shareholders general meeting on June 26, 2025, where approximately 57% of voting rights were exercised, resulting in the adoption of resolutions 1 through 23 and resolutions 25 and 26, while resolution 24 was rejected [2] - Mr. André Muller was appointed to the Board of Directors, while Mr. Axel-Sven Malkomes' term expired and Mr. Pierre Bastid's resignation became effective [3][4] - The Chairman of the Board, Jean-Pierre Garnier, expressed gratitude for the contributions of the departing directors and highlighted Mr. Muller's extensive experience as an asset to the company [5] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using a pioneering gene-editing platform [6] - The company specializes in an allogeneic approach for CAR T immunotherapies in oncology, aiming to provide off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [6] - Cellectis maintains in-house manufacturing capabilities, positioning itself as one of the few end-to-end gene editing companies that control the entire cell and gene therapy value chain [6][7]

Core Insights - Klotho Neurosciences, Inc. has terminated its Share Exchange Agreement with SkyBell Technologies, allowing the company to focus on its core R&D programs and enhance shareholder value [2][3] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company specializing in innovative, disease-modifying cell and gene therapies derived from the anti-aging human Klotho gene, targeting neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease [4] Strategic Implications - The termination of the agreement eliminates the need to issue new common stock to SkyBell, which would have resulted in SkyBell owning 90% of Klotho, thereby preventing significant dilution of existing shareholders [7] - The company will not incur any liability as a result of this termination, allowing it to refocus its strategy and allocate resources towards advancing its primary therapeutic and longevity programs [7]

Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using its gene-editing platform [2][3] - The company employs an allogeneic approach for CAR T immunotherapies in oncology, introducing off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [2] - Cellectis has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that manage the entire cell and gene therapy value chain [2] Upcoming Events - Cellectis will hold its annual general meeting on June 26, 2025, at 2:30 p.m. CET in Paris, France [1] - Detailed agenda and modalities for participation in the meeting are available on the Cellectis website [2]

Core Points - Cellectis, a clinical-stage biotechnology company, will hold its annual general meeting on June 26, 2025, at 2:30 p.m. CET in Paris, France [1] - The company specializes in developing life-saving cell and gene therapies using its gene-editing platform [2][3] - Cellectis employs an allogeneic approach for CAR T immunotherapies, focusing on off-the-shelf gene-edited CAR T-cells for cancer treatment [2] - The company has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that control the entire value chain [2] Company Information - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC [3] - The company is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [3] - For more information, Cellectis provides contact details for media and investor relations [4]

Core Viewpoint - Cellectis, a clinical-stage biotechnology company, is set to report its financial results for Q1 2025 on May 12, 2025, after the US market closes [1]. Company Overview - Cellectis specializes in developing life-saving cell and gene therapies using its innovative gene-editing platform [2][3]. - The company employs an allogeneic approach for CAR T immunotherapies in oncology, focusing on off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [2]. - Cellectis is one of the few end-to-end gene editing companies, controlling the entire cell and gene therapy value chain from start to finish through its in-house manufacturing capabilities [2]. Locations and Listings - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC [3]. - The company is publicly traded on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS [3].